but kind of an end point is that when we look at new endogenous substances, can we develop a thought process or a decision tree, if you will, of various factors that are important in determining how we're going to deal with that particular substance? Do we or do we not subtract baseline? How are we going to measure it? At what dose? Is it going to be even possible to use our normal, I think, well-accepted and reliable plasma concentrations or are we going to have to go to yet another scheme or another area of measurement to try and develop an understanding about bioequivalence methods that are going to assure that those products behave in an equivalent manner?
So that's the endpoint that we're looking for as an overall scientific construction of thought about how to approach these products, how to look at the various variables and characteristics of a new endogenous product and how to construct a proper way to do formulation comparisons.
DR. KIBBE: I guess now is a good opportunity for those of you who have been taking copious notes on the presentations in sequence to ask questions. Wolfgang is